| [1] |
Ayodele O, Razak ARA. Immunotherapy in soft-tissue sarcoma[J]. Curr Oncol, 2020, 27: 17-23. DOI: 10.3747/co.27.5407.
pmid: 32174754
|
| [2] |
Thway K. What's new in adipocytic neoplasia?[J]. Histopathology, 2022, 80(1): 76-97. DOI: 10.1111/his.14548.
pmid: 34958506
|
| [3] |
Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives[J]. Pathologica, 2021, 113(2): 70-84. DOI: 10.32074/1591-951X-213.
pmid: 33179614
|
| [4] |
Lee ATJ, Thway K, Huang PH, et al. Clinical and molecular spectrum of liposarcoma[J]. J Clin Oncol, 2018, 36(2): 151-159. DOI: 10.1200/JCO.2017.74.9598.
pmid: 29220294
|
| [5] |
Zaidi MY, Canter R, Cardona K. Post-operative surveillance in retroperitoneal soft tissue sarcoma: the importance of tumor histology in guiding strategy[J]. J Surg Oncol, 2018, 117(1): 99-104. DOI: 10.1002/jso.24927.
pmid: 29193081
|
| [6] |
Gahvari Z, Parkes A. Dedifferentiated liposarcoma: systemic therapy options[J]. Curr Treat Options Oncol, 2020, 21(2): 15. DOI: 10. 1007/s11864-020-0705-7.
|
| [7] |
Bourcier K, Le Cesne A, Tselikas L, et al. Basic knowledge in soft tissue sarcoma[J]. Cardiovasc Intervent Radiol, 2019, 42(9): 1255-1261. DOI: 10.1007/s00270-019-02259-w.
pmid: 31236647
|
| [8] |
Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. J Hematol Oncol, 2018, 11(1): 120. DOI: 10.1186/s13045-018-0664-7.
|
| [9] |
Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma[J]. Clin Cancer Res, 2018, 24(21): 5233-5238. DOI: 10.1158/1078-0432.CCR-17-3766.
pmid: 29895706
|
| [10] |
Zhang RS, Liu J, Deng YT, et al. The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era[J]. Cancer Med, 2022, 11(11): 2271-2283. DOI: 10.1002/cam4.4613.
|
| [11] |
Chi Y, Yao Y, Fang Z, et al. Evaluation of thyroid-stimulating hormone-increased, hypertriglyceridemia and proteinuria as markers of anlotinib efficacy in advanced soft tissue sarcoma[J]. J Clin Oncol, 2020, 38(15_suppl): e23548. DOI: 10.1200/JCO.2020.38.15_suppl.e23548.
|
| [12] |
Wilky BA, Trucco MM, Subhawong TK, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial[J]. Lancet Oncol, 2019, 20(6): 837-848. DOI: 10.1016/S1470-2045(19)30153-6.
pmid: 31078463
|
| [13] |
Keung EZ, Burgess M, Salazar R, et al. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab[J]. Clin Cancer Res, 2020, 26(6): 1258-1266. DOI: 10.1158/1078-0432.CCR-19-1824.
pmid: 31900276
|
| [14] |
Petitprez F, de Reyniès A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma[J]. Nature, 2020, 577(7791): 556-560. DOI: 10.1038/s41586-019-1906-8.
|
| [15] |
Sun X, Xu J, Xie L, et al. Effectiveness and tolerability of anlotinib plus PD-1 inhibitors for patients with previously treated metastatic soft-tissue sarcoma[J]. Int J Gen Med, 2022, 15: 7581-7591. DOI: 10.2147/IJGM.S379269.
pmid: 36196372
|
| [16] |
Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26: 677-704. DOI: 10.1146/annurev.immunol.26.021607.090331.
pmid: 18173375
|
| [17] |
Gronchi A. Surgery in soft tissue sarcoma: the thin line between a surgical or more conservative approach[J]. Future Oncol, 2021, 17(21s): 3-6. DOI: 10.2217/fon-2021-0449.
pmid: 34107729
|
